Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 39, Pages 15859-15864Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1213409109
Keywords
-
Categories
Funding
- Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery
- NIH [AI081677]
- The German National Academic Foundation
- German Research Foundation [KL 2389/1-1]
- American Liver Foundation
Ask authors/readers for more resources
Passive transfer of neutralizing antibodies against HIV-1 can prevent infection in macaques and seems to delay HIV-1 rebound in humans. Anti-HIV antibodies are therefore of great interest for vaccine design. However, the basis for their in vivo activity has been difficult to evaluate systematically because of a paucity of small animal models for HIV infection. Here we report a genetically humanized mouse model that incorporates a luciferase reporter for rapid quantitation of HIV entry. An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available